| Identification | Back Directory | [Name]
4-[4-[Bis(4-fluorophenyl)methyl]-1-piperazinyl]-6-bromo-1-methyl-3-nitro-1,5-naphthyridin-2(1H)-one | [CAS]
2407854-31-1 | [Synonyms]
4-[4-[Bis(4-fluorophenyl)methyl]-1-piperazinyl]-6-bromo-1-methyl-3-nitro-1,5-naphthyridin-2(1H)-one | [Molecular Formula]
C26H22BrF2N5O3 | [MOL File]
2407854-31-1.mol | [Molecular Weight]
570.39 |
| Chemical Properties | Back Directory | [Boiling point ]
611.5±55.0 °C(Predicted) | [density ]
1.61±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
6.33±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ)[1]. | [References]
[1] Wichroski M, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023;15(719):eadh1892. DOI:10.1126/scitranslmed.adh1892 |
|
|